Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc (TOVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results GlobeNewswire - Wed Nov 12, 7:00AM CST

- Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial presented at the European Society for Medical Oncology (ESMO)...

TOVX : 0.2255 (-6.66%)
Theriva Biologics Provides Response to Unusual Market Action GlobeNewswire - Fri Oct 24, 1:31PM CDT

ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed...

TOVX : 0.2255 (-6.66%)
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds GlobeNewswire - Thu Oct 16, 7:11AM CDT

ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed...

TOVX : 0.2255 (-6.66%)
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings GlobeNewswire - Mon Oct 13, 7:00AM CDT

- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 - - SYN-004 Interim blinded safety and pharmacokinetic data to be presented at IDWeek 2025 - Rockville, Md.,...

TOVX : 0.2255 (-6.66%)
Theriva Biologics Unveils VCN-12 Preclinical Data Tipranks - Tue Oct 7, 7:44AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Theriva Biologics...

TOVX : 0.2255 (-6.66%)
Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) GlobeNewswire - Mon Oct 6, 7:00AM CDT

- Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects - -...

TOVX : 0.2255 (-6.66%)
Theriva Biologics Restructures, Cuts Workforce by 32% Tipranks - Fri Oct 3, 3:42PM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Theriva Biologics...

TOVX : 0.2255 (-6.66%)
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results GlobeNewswire - Mon Aug 11, 7:00AM CDT

- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in...

TOVX : 0.2255 (-6.66%)
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer GlobeNewswire - Tue May 27, 7:00AM CDT

TOVX : 0.2255 (-6.66%)
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results GlobeNewswire - Wed May 14, 7:40AM CDT

TOVX : 0.2255 (-6.66%)

Barchart Exclusives

Rate Decision, Tech Earnings and Other Key Things to Watch this Week Barchart - Sun Dec 7, 12:00PM CST
Markets face the year's final major policy week as the Federal Reserve's December meeting Wednesday afternoon will determine whether the central bank delivers another rate cut or pauses its easing cycle amid mixed economic signals and persistent inflation concerns. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot